A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression
The PRG risk signature serves as a promising biomarker for evaluating peroxisomal activity, prognosis, and responsiveness to immunotherapy in breast cancer.
Authors
- Sheng Xu (ORCID: https://orcid.org/0000-0002-9547-8052)
- Junfeng Liu (ORCID: https://orcid.org/0000-0002-9988-4349)
- Yunxiang Wang (ORCID: https://orcid.org/0000-0002-9286-1881)
- Qi Pan (ORCID: https://orcid.org/0000-0001-8542-0925)
Institutions
- Xinxiang Central Hospital (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/bctt.s490154
- Citations
- 4
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.94